Global Brinzolamide Market 2023-2030

    In Stock

    Coming Soon.




    A carbonic anhydrase inhibitor called brinzolamide is used to reduce intraocular pressure in people with open-angle glaucoma or ocular hypertension. A generic version of brinzolamide has received approval. A group of drugs known as carbonic anhydrase inhibitors includes brinzolamide.


    It lowers the pressure inside the eye. Brinzolamide (Azopt) is an eye drop used to treat glaucoma and reduce eye pressure. Once opened, eye drops in bottles only last for four weeks, therefore if the bottle has been open for more time than this, do not use the drops. This will lessen the chance of developing eye infections.


    It’s time to give up fried food, baked goods, and anything whose ingredient list contains hydrogenated or partially hydrogenated oils. Red meat, steak, lard, shortening, and oils are examples of saturated diets that might aggravate glaucoma.




    Infographic: Brinzolamide Market, Brinzolamide Market Size, Brinzolamide Market Trends, Brinzolamide Market Forecast, Brinzolamide Market Risks, Brinzolamide Market Report, Brinzolamide Market Share


    The Global BRINZOLAMIDE market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    Teva Pharmaceuticals’ release of Brinzolamide Ophthalmic Suspension 1% in the US market was announced by Indoco. The first generic version of AZOPT® from Teva Pharmaceuticals, Brinzolamide Ophthalmic Suspension 1%, has been made available in the United States by Indoco Remedies.


    At its Goa factory, Indoco Remedies Ltd. creates and produces the product for TEVA. The ANDA for Brinzolamide Ophthalmic Suspension 1% was approved by the US Food and Drug Administration and is used to treat open-angle glaucoma and excessive pressure inside the eye caused by ocular hypertension.


    The action of Brinzolamide Ophthalmic Suspension 1% is to lessen the fluid content of the eye.


    The fact that Indoco was the first to introduce a generic version of AZOPT® (Brinzolamide Ophthalmic Suspension 1%, created by Indoco) onto the American market presents a significant potential for Indoco to provide patients with a generic alternative.


    Additionally, it gives us great pleasure to have assisted in the process of creating complex generic drugs (ophthalmic suspensions) and obtaining US regulatory approval for them, thereby guaranteeing that people have access to high-quality, reasonably priced medications.


    With the manufacturing of Brinzolamide API at the Patalganga plant, Indoco has a competitive advantage in ensuring the continuation of commercial supplies.





    1. How many BRINZOLAMIDE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global BRINZOLAMIDE and key vendor selection criteria
    3. Where is the BRINZOLAMIDE manufactured? What is the average margin per unit?
    4. Market share of Global BRINZOLAMIDE market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global BRINZOLAMIDE in-house
    6. key predictions for next 5 years in Global BRINZOLAMIDE market
    7. Average B-2-B BRINZOLAMIDE market price in all segments
    8. Latest trends in BRINZOLAMIDE market, by every market segment
    9. The market size (both volume and value) of the BRINZOLAMIDE market in 2023-2030 and every year in between?
    10. Production breakup of BRINZOLAMIDE market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop